ArticleClinical and molecular hepatology2026
Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson's disease.
Article in Clinical and molecular hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND/
aimsWilson's disease (WD) is an autosomal recessive disorder of copper metabolism caused by Atp7b mutations. In this study, a novel gene therapy for WD was developed, and its efficacy and safety were evaluated in relevant animal models.
methodsCodon-optimized full-length or truncated ATP7B (tATP7B) genes were assembled with liver-specific mini promoters to construct an adeno-associated virus serotype 8 vector (AAV8). The expression and activity of these vectors were evaluated in HepG2 cells. AAV8-tATP7B viral particles were produced using a triple-plasmid cotransfection system under good manufacturing practice conditions. Long-term efficacy was evaluated in Atp7b-/- mice at three doses (5×10¹¹, 5×10¹², and 1×10¹³ vg/kg). Single-dose toxicity was assessed over 13 weeks in Sprague- Dawley rats and cynomolgus macaques.
resultsIn HepG2 cells, the ability of the tATP7B to export copper was comparable to that of the full-length protein, but the expression efficiency was greater. Alkaline gel electrophoresis confirmed its better compatibility with AAV packaging limits while maintaining genomic integrity, supporting its selection for AAV8-tATP7B production. In a 24- week study in Atp7b-/- mice, AAV8-tATP7B restored copper homeostasis and liver function in a dose-dependent manner and significantly reversed existing liver injury. Toxicity studies in Sprague‒Dawley rats and cynomolgus monkeys revealed no systemic toxicity, whereas reversible liver changes were observed in cynomolgus monkeys at high doses; thus, 6×10¹³ vg/kg was established as the maximum tolerated dose.
conclusionsThese results establish the efficacy and safety profile of AAV8-tATP7B and provide the rationale for its clinical translation in patients with WD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.